Welcome to our dedicated page for KAIROS PHARMA news (Ticker: KAPA), a resource for investors and traders seeking the latest updates and insights on KAIROS PHARMA stock.
Kairos Pharma, Ltd. (NYSE American: KAPA) is a Los Angeles-based clinical-stage biopharmaceutical company focused on oncology therapeutics that address drug resistance and immune suppression in cancer. Its news flow is driven by clinical trial updates, scientific presentations, licensing developments, and corporate events related to its pipeline of targeted cancer therapies.
The company’s lead candidate, ENV105, is an antibody targeting CD105, a protein it identifies as a key driver of resistance to various cancer treatments. News releases frequently cover interim safety and efficacy results from the randomized Phase 2 trial of ENV105 in combination with apalutamide in metastatic castration-resistant prostate cancer, including progression-free survival data, prostate-specific antigen (PSA) responses, and safety findings from early patient cohorts. Additional coverage highlights Phase 1 data of ENV105 in combination with osimertinib in advanced EGFR‑mutated non-small cell lung cancer.
Visitors to this page can review announcements about Kairos Pharma’s participation in major oncology conferences such as the European Society for Medical Oncology Congress and the World Lung Cancer Conference, where the company presents clinical and preclinical data. The news feed also includes updates on key opinion leader events, Department of Defense grants supporting research on ENV105 and ENV205, and preclinical findings on other pipeline candidates like KROS101 and KROS401 in tumor types such as melanoma and glioblastoma.
In addition to scientific and clinical milestones, Kairos Pharma issues news about investor conference presentations and corporate communications that outline its development strategy and focus on high unmet medical needs in cancer. Investors and researchers can use this news page to follow how Kairos Pharma reports the progress of its CD105-targeted programs and broader oncology pipeline over time.
Kairos Pharma (NYSE:KAPA) signed binding terms to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics on March 2, 2026. CL-273 is an AI-designed, reversible, wild-type-sparing pan‑EGFR inhibitor targeting EGFR‑mutant NSCLC and resistance mechanisms.
The deal expands Kairos’s oncology pipeline into a market estimated at $16.2 billion in 2026 and is described by the company as expected to be value-accretive; D. Boral Capital acted as sole financial advisor.
Kairos Pharma (NYSE:KAPA) signed a term sheet to acquire worldwide rights to two clinical oncology assets from Celyn Therapeutics: CL-273, a pre‑IND wild‑type‑sparing pan‑EGFR inhibitor, and CL-741, a Phase 1‑ready oral type IIb c‑MET inhibitor. CL-273 completed GLP toxicology and is projected for first‑in‑human trials in 2026. The pairing targets EGFR-mutant and MET-driven NSCLC resistance mechanisms, supports a differentiated dual‑inhibition strategy, and cites a 4–5× wider therapeutic window for CL-273 and favorable brain/lung permeability. The agreement is a term sheet and remains subject to completion.
Kairos Pharma (NYSE American: KAPA) will participate in the 3rd Annual DealFlow Discovery Conference at The Borgata Hotel in Atlantic City, NJ on Jan. 28-29, 2026. Chief Scientific Officer Neil Bhowmick will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Investors may request an investor pass at the conference website; the announcement states there is no cost to attend.
Kairos Pharma (NYSE: KAPA) won the 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer for advancing ENV-105 (carotuximab), a first-in-class CD105-targeting monoclonal antibody designed to modulate resistance pathways in metastatic castration-resistant prostate cancer (mCRPC).
The company reported positive interim Phase 2 safety and efficacy data for ENV-105 combined with apalutamide: clinical benefit in 86% of treated patients to date; all responders were progression-free for at least 4 months, and half remained progression-free beyond 1 year. ENV-105 is investigational and has not been approved by the FDA or comparable foreign regulators.
Kairos Pharma (NYSE:KAPA) provided a shareholder update on November 4, 2025 outlining 2025 progress and 2026 outlook. Key clinical highlights include positive interim Phase 2 safety and efficacy results for ENV105 + apalutamide in metastatic prostate cancer: 86% clinical benefit rate among treated patients, median PFS 13.7 months by imaging, PSA reductions in 7 of 9 evaluable patients, and no dose‑limiting or Grade 4/5 toxicities.
Other 2025 achievements: presentations at ESMO, ASCO and AACR IO, peer‑review publication on CD105, and Department of Defense grants supporting ENV105 and ENV205. Planned 2026 milestones include completing Phase 2 enrollment (up to 100 patients), ongoing Phase 1 work in NSCLC, additional publications, and partnership announcements.
Kairos Pharma (NYSE American: KAPA) presented interim Phase 2 efficacy data for ENV-105 (carotuximab) in metastatic castration-resistant prostate cancer at the ESMO meeting on October 20, 2025. The interim analysis reported a clinical benefit in 86% of treated patients when ENV-105 was combined with apalutamide, with all responders progression-free at least 4 months and half remaining progression-free beyond 1 year. Seven of nine evaluable patients showed PSA reductions from baseline. Imaging-reported median progression-free survival with the combination was 13.7 months. The randomized Phase 2 is actively accruing up to 100 patients across three U.S. cancer centers; results are interim and the trial is ongoing.
Kairos Pharma (NYSE American: KAPA) will present interim Phase 2 safety and clinical-activity data for ENV105 (carotuximab) combined with apalutamide in advanced, castration-resistant prostate cancer at the ESMO Congress, Oct 17–21, 2025 in Berlin.
The randomized trial is enrolling 100 men at Cedars-Sinai, City of Hope, and Huntsman Cancer Institute; patients receive apalutamide with or without ENV105. Kairos describes the interim analysis as showing encouraging safety and early efficacy. Study identifier: NCT05534646. The company framed results as preliminary and cautioned that forward-looking statements are subject to risks and uncertainties.
Kairos Pharma (NYSE American: KAPA) has announced positive interim efficacy data from its Phase 2 clinical trial of ENV105 (carotuximab) in metastatic castration-resistant prostate cancer (mCRPC) patients. The trial demonstrated a remarkable median progression-free survival of 13 months when ENV105 was combined with apalutamide.
Key findings include: 7 out of 9 patients showed decreased PSA levels, and 5 out of 8 evaluable patients continue treatment without progression. The results significantly exceeded the trial's target of 45% PFS improvement from 3.7 to 6.7 months. The study, which aims to enroll 100 patients total, follows July's positive safety analysis showing no Grade 3 or 4 toxicities.
The company is conducting the trial at multiple prestigious centers and will host a KOL event featuring leading experts to discuss these promising results.Kairos Pharma (NYSE American: KAPA) has announced a virtual KOL event scheduled for September 18th, 2025 to discuss interim efficacy results of its Phase 2 trial for ENV105 in advanced prostate cancer treatment. The event will feature distinguished experts including the company's CSO and leading oncologists from prestigious institutions.
The announcement follows positive interim safety results from July 2025, where ENV105, a first-in-class CD105 antagonist, demonstrated good tolerability when combined with apalutamide. The trial showed no dose-limiting toxicities, unexpected adverse events, or Grade 3/4 toxicities in the first 10 patients.
ENV105 aims to address the growing challenge of castration-resistant prostate cancer, affecting one million men annually in the US who develop resistance to current hormone therapies.
Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming World Lung Cancer Conference, where initial Phase 1 data for ENV105 in non-small cell lung cancer will be presented. The presentation, led by Principal Investigator Dr. Karen Reckamp, will focus on the combination therapy of ENV105 with osimertinib for treating EFGR-mutated non-small cell lung cancer.
The open-label trial aims to evaluate the safety and tolerability of this combination therapy. The conference will take place from September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain.